Mirati Therapeutics (MRTX) – Corporate News
-
Bristol-Myers Squibb (BMY) Completes Acquisition of Mirati Therapeutics (MRTX)
-
Mirati Therapeutics (MRTX) Announces European Commission Approves KRAZATI as Targeted Treatment Option for Patients with Advanced NSCLC with a KRASG12C Mutation
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to MRTX Stock Lookup